<DOC>
	<DOCNO>NCT00442598</DOCNO>
	<brief_summary>Primary Objectives : - To evaluate effect glufosfamide serum concentration CA125 subject ovarian cancer - To evaluate safety weekly glufosfamide dose subject ovarian cancer compare every 21-day dosing Secondary objective : - To evaluate efficacy glufosfamide subject ovarian cancer measure objective response rate , duration response , progression-free survival , overall survival - To evaluate pharmacokinetics glufosfamide isophosphoramide mustard treatment Exploratory objective : - To correlate efficacy endpoint expression tumor-associated glucose transporter protein</brief_summary>
	<brief_title>Safety Efficacy Study Glufosfamide Ovarian Cancer</brief_title>
	<detailed_description>Open-label , multicenter , Phase 2 dose escalation study . Subjects randomize receive either every three week dose regimen weekly dose regimen . Randomization utilize 2:1 ratio two-thirds subject randomized weekly dose regimen . In weekly dosing schedule , treatment glufosfamide 2,500 mg/m2 initiate 1,660 mg/m2 treatment cohort enrol evidence dose 1,660 mg/m2 well tolerate ( See Section Pharmacokinetic/Statistical Analyses ) .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>At least 18 year age Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee Pathologically confirm epithelial ovarian cancer , peritoneal serous cancer , carcinoma fallopian tube Prior treatment least one platinumbased chemotherapy Evidence resistance recent platinumcontaining regimen ( relapse within 6 month complete chemotherapy ) Evidence CA 125 progression recent chemotherapy define either : CA 125 least 40 U/mL patient elevate CA 125 decrease &lt; 20 U/mL therapy ; CA 125 least 40 U/mL least 50 % increase nadir value patient elevate CA 125 decrease &lt; 20 U/mL therapy . CA 125 must meet criterion two occasion less one week apart CA 125 increase least 100 % ( i.e. , double ) . There must 3 consecutive increase measurement period least two week CA 125 increase least 50 % le 100 % . Elevated serum CA125 ( ≥40 U/mL ) within 2 week prior start treatment At least one target nontarget lesion RECIST A minimum 21 day prior chemotherapy , radiation therapy , immunotherapy , antitumor therapy study entry Recovered reversible toxicity prior therapy ECOG score 0 1 ANC ≥ 1,500/µL , platelet ≥ 100,000/µL , hemoglobin ≥9 g/dL Total bilirubin ≤ 1.5fold ULN , AST/ALT ≤ 2.5fold ULN ( ≤ 5fold ULN liver metastasis ) Creatinine clearance ≥ 60 mL/min ( calculate CockcroftGault formula ) All woman childbearing potential must negative serum pregnancy test must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) entry study 6 month last dose Concomitant plan hormonal therapy , radiation therapy , biologic therapy , chemotherapy systemic antitumor therapy ovarian cancer protocol therapy Symptomatic brain metastasis Active clinically significant infection require antibiotic Known HIV positive active hepatitis B C Recent ( one year ) history symptom cardiovascular disease ( NYHA Class 2 , 3 , 4 ) , particularly coronary artery disease , arrhythmias conduction defect risk cardiovascular instability , uncontrolled hypertension , clinically significant pericardial effusion , congestive heart failure stroke Other active malignancy ( treat nonmelanoma skin cancer treat situ cancer ) within past 5 year Major surgery within 3 week start study treatment , without complete recovery Females pregnant breastfeed Participation investigational drug device study within 28 day first day dose study Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk subject study Unwillingness inability comply study protocol reason</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>Cancer</keyword>
	<keyword>CA-125</keyword>
	<keyword>Third-line</keyword>
	<keyword>Glufosfamide</keyword>
</DOC>